Marc Beer has taken the fight against pelvic floor disorders to the next level by securing financing for his women health startup, Renovia, Inc. He successfully raised $42 million in venture debt and Series B round. The women health startup now is set to move forward with development of four main products including the new generation of the Leva device. Renovia is a pharmaceutical company that is committed to improve the lives of women living with pelvic floor disorders around the world.
According to a research, urinary incontinence affects over 250 million women across the world. Mr. Marc Beer’s company has been dedicated to developing diagnostic and therapeutic products to treat the disorders. Since inception, the company has made incredible progress with some of its products receiving FDA approval. The company’s Leva device received FDA approval in April this year.
He raised $32 million in Series B round and $10 million in venture debt. Big players in the healthcare industry participated in Series B round conducted by the New York-based Perceptive Advisors and Missouri-based Ascension Ventures. The funding will boost the company’s efforts significantly with the development of the four pelvic floor disorder treatment products.
Marc Beer was excited by the move of the players in the industry to support him in his fight against the disorders. He has so far received unwavering support from the leading investors in the healthcare industry. He said in a statement that the investors shares his vision of improving the lives of women across the world who are suffering from pelvic floor disorders. Using cutting edge technology and solutions, he aims to make valuable data accessible to customers. The data generated will inform better pelvic floor disorder treatment options, build on the existing knowledge and eventually, promote the understanding of the disorders. The efforts are directed towards reduce healthcare costs in the long-run. Learn more: https://renoviainc.com/leadership/
The renowned healthcare entrepreneur has led a noble career in the industry. He was a strategic consultant in OvaScience, a pharmaceutical company which later merged with Millendo Therapeutics. Marc Beer is the CEO as well as Co-founder of Renovia, a Boston-based medtech company. He has over 25 years of experience in the industry with a specialty on development and commercialization in biotechnology, pharmaceutical, diagnostic as well as device industries. He a BS graduate from Miami University, OHIO.
He founded ViaCell and established it over time to have over 300 employees and later, go public. The company was acquired in 2007 by PerkinElmer. He is also a member of the board of directors of Erytech Pharmaceuticals. Marc Beer is also the Founding Chairman of committee of Good Start Genetics’ board of directors. He also holds prestigious positions in Minerva Neurosciences. He is also a member of Miami University Business Advisory Council. He served in other prestigious positions.